1
|
Miressi F, Benslimane N, Favreau F, Rassat M, Richard L, Bourthoumieu S, Laroche C, Magy L, Magdelaine C, Sturtz F, Lia AS, Faye PA. GDAP1 Involvement in Mitochondrial Function and Oxidative Stress, Investigated in a Charcot-Marie-Tooth Model of hiPSCs-Derived Motor Neurons. Biomedicines 2021; 9:biomedicines9080945. [PMID: 34440148 PMCID: PMC8393985 DOI: 10.3390/biomedicines9080945] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2021] [Revised: 07/27/2021] [Accepted: 07/29/2021] [Indexed: 12/15/2022] Open
Abstract
Mutations in the ganglioside-induced differentiation associated protein 1 (GDAP1) gene have been associated with demyelinating and axonal forms of Charcot-Marie-Tooth (CMT) disease, the most frequent hereditary peripheral neuropathy in humans. Previous studies reported the prevalent GDAP1 expression in neural tissues and cells, from animal models. Here, we described the first GDAP1 functional study on human induced-pluripotent stem cells (hiPSCs)-derived motor neurons, obtained from normal subjects and from a CMT2H patient, carrying the GDAP1 homozygous c.581C>G (p.Ser194*) mutation. At mRNA level, we observed that, in normal subjects, GDAP1 is mainly expressed in motor neurons, while it is drastically reduced in the patient’s cells containing a premature termination codon (PTC), probably degraded by the nonsense-mediated mRNA decay (NMD) system. Morphological and functional investigations revealed in the CMT patient’s motor neurons a decrease of cell viability associated to lipid dysfunction and oxidative stress development. Mitochondrion is a key organelle in oxidative stress generation, but it is also mainly involved in energetic metabolism. Thus, in the CMT patient’s motor neurons, mitochondrial cristae defects were observed, even if no deficit in ATP production emerged. This cellular model of hiPSCs-derived motor neurons underlines the role of mitochondrion and oxidative stress in CMT disease and paves the way for new treatment evaluation.
Collapse
Affiliation(s)
- Federica Miressi
- Maintenance Myélinique et Neuropathies Périphériques, EA6309, University of Limoges, F-87000 Limoges, France; (N.B.); (F.F.); (M.R.); (L.R.); (S.B.); (L.M.); (C.M.); (F.S.); (A.-S.L.); (P.-A.F.)
- Correspondence:
| | - Nesrine Benslimane
- Maintenance Myélinique et Neuropathies Périphériques, EA6309, University of Limoges, F-87000 Limoges, France; (N.B.); (F.F.); (M.R.); (L.R.); (S.B.); (L.M.); (C.M.); (F.S.); (A.-S.L.); (P.-A.F.)
| | - Frédéric Favreau
- Maintenance Myélinique et Neuropathies Périphériques, EA6309, University of Limoges, F-87000 Limoges, France; (N.B.); (F.F.); (M.R.); (L.R.); (S.B.); (L.M.); (C.M.); (F.S.); (A.-S.L.); (P.-A.F.)
- CHU Limoges, Service de Biochimie et Génétique Moléculaire, F-87000 Limoges, France
| | - Marion Rassat
- Maintenance Myélinique et Neuropathies Périphériques, EA6309, University of Limoges, F-87000 Limoges, France; (N.B.); (F.F.); (M.R.); (L.R.); (S.B.); (L.M.); (C.M.); (F.S.); (A.-S.L.); (P.-A.F.)
| | - Laurence Richard
- Maintenance Myélinique et Neuropathies Périphériques, EA6309, University of Limoges, F-87000 Limoges, France; (N.B.); (F.F.); (M.R.); (L.R.); (S.B.); (L.M.); (C.M.); (F.S.); (A.-S.L.); (P.-A.F.)
- CHU Limoges, Service de Neurologie, F-87000 Limoges, France
| | - Sylvie Bourthoumieu
- Maintenance Myélinique et Neuropathies Périphériques, EA6309, University of Limoges, F-87000 Limoges, France; (N.B.); (F.F.); (M.R.); (L.R.); (S.B.); (L.M.); (C.M.); (F.S.); (A.-S.L.); (P.-A.F.)
- CHU Limoges, Service de Cytogénétique, F-87000 Limoges, France
| | - Cécile Laroche
- CHU Limoges, Service de Pédiatrie, F-87000 Limoges, France;
- CHU Limoges, Centre de Compétence des Maladies Héréditaires du Métabolisme, F-87000 Limoges, France
| | - Laurent Magy
- Maintenance Myélinique et Neuropathies Périphériques, EA6309, University of Limoges, F-87000 Limoges, France; (N.B.); (F.F.); (M.R.); (L.R.); (S.B.); (L.M.); (C.M.); (F.S.); (A.-S.L.); (P.-A.F.)
- CHU Limoges, Service de Neurologie, F-87000 Limoges, France
| | - Corinne Magdelaine
- Maintenance Myélinique et Neuropathies Périphériques, EA6309, University of Limoges, F-87000 Limoges, France; (N.B.); (F.F.); (M.R.); (L.R.); (S.B.); (L.M.); (C.M.); (F.S.); (A.-S.L.); (P.-A.F.)
- CHU Limoges, Service de Biochimie et Génétique Moléculaire, F-87000 Limoges, France
| | - Franck Sturtz
- Maintenance Myélinique et Neuropathies Périphériques, EA6309, University of Limoges, F-87000 Limoges, France; (N.B.); (F.F.); (M.R.); (L.R.); (S.B.); (L.M.); (C.M.); (F.S.); (A.-S.L.); (P.-A.F.)
- CHU Limoges, Service de Biochimie et Génétique Moléculaire, F-87000 Limoges, France
| | - Anne-Sophie Lia
- Maintenance Myélinique et Neuropathies Périphériques, EA6309, University of Limoges, F-87000 Limoges, France; (N.B.); (F.F.); (M.R.); (L.R.); (S.B.); (L.M.); (C.M.); (F.S.); (A.-S.L.); (P.-A.F.)
- CHU Limoges, Service de Biochimie et Génétique Moléculaire, F-87000 Limoges, France
- CHU Limoges, Service de Bioinformatique, F-87000 Limoges, France
| | - Pierre-Antoine Faye
- Maintenance Myélinique et Neuropathies Périphériques, EA6309, University of Limoges, F-87000 Limoges, France; (N.B.); (F.F.); (M.R.); (L.R.); (S.B.); (L.M.); (C.M.); (F.S.); (A.-S.L.); (P.-A.F.)
- CHU Limoges, Service de Biochimie et Génétique Moléculaire, F-87000 Limoges, France
| |
Collapse
|
2
|
McKnight CL, Low YC, Elliott DA, Thorburn DR, Frazier AE. Modelling Mitochondrial Disease in Human Pluripotent Stem Cells: What Have We Learned? Int J Mol Sci 2021; 22:7730. [PMID: 34299348 PMCID: PMC8306397 DOI: 10.3390/ijms22147730] [Citation(s) in RCA: 13] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/30/2021] [Revised: 07/16/2021] [Accepted: 07/16/2021] [Indexed: 02/06/2023] Open
Abstract
Mitochondrial diseases disrupt cellular energy production and are among the most complex group of inherited genetic disorders. Affecting approximately 1 in 5000 live births, they are both clinically and genetically heterogeneous, and can be highly tissue specific, but most often affect cell types with high energy demands in the brain, heart, and kidneys. There are currently no clinically validated treatment options available, despite several agents showing therapeutic promise. However, modelling these disorders is challenging as many non-human models of mitochondrial disease do not completely recapitulate human phenotypes for known disease genes. Additionally, access to disease-relevant cell or tissue types from patients is often limited. To overcome these difficulties, many groups have turned to human pluripotent stem cells (hPSCs) to model mitochondrial disease for both nuclear-DNA (nDNA) and mitochondrial-DNA (mtDNA) contexts. Leveraging the capacity of hPSCs to differentiate into clinically relevant cell types, these models permit both detailed investigation of cellular pathomechanisms and validation of promising treatment options. Here we catalogue hPSC models of mitochondrial disease that have been generated to date, summarise approaches and key outcomes of phenotypic profiling using these models, and discuss key criteria to guide future investigations using hPSC models of mitochondrial disease.
Collapse
Affiliation(s)
- Cameron L. McKnight
- Murdoch Children’s Research Institute, Royal Children’s Hospital, Parkville, VIC 3052, Australia; (C.L.M.); (Y.C.L.); (D.A.E.); (D.R.T.)
- Department of Paediatrics, University of Melbourne, Parkville, VIC 3052, Australia
| | - Yau Chung Low
- Murdoch Children’s Research Institute, Royal Children’s Hospital, Parkville, VIC 3052, Australia; (C.L.M.); (Y.C.L.); (D.A.E.); (D.R.T.)
- Department of Paediatrics, University of Melbourne, Parkville, VIC 3052, Australia
| | - David A. Elliott
- Murdoch Children’s Research Institute, Royal Children’s Hospital, Parkville, VIC 3052, Australia; (C.L.M.); (Y.C.L.); (D.A.E.); (D.R.T.)
- Department of Paediatrics, University of Melbourne, Parkville, VIC 3052, Australia
| | - David R. Thorburn
- Murdoch Children’s Research Institute, Royal Children’s Hospital, Parkville, VIC 3052, Australia; (C.L.M.); (Y.C.L.); (D.A.E.); (D.R.T.)
- Department of Paediatrics, University of Melbourne, Parkville, VIC 3052, Australia
- Victorian Clinical Genetics Services, Royal Children’s Hospital, Parkville, VIC 3052, Australia
| | - Ann E. Frazier
- Murdoch Children’s Research Institute, Royal Children’s Hospital, Parkville, VIC 3052, Australia; (C.L.M.); (Y.C.L.); (D.A.E.); (D.R.T.)
- Department of Paediatrics, University of Melbourne, Parkville, VIC 3052, Australia
| |
Collapse
|
3
|
Abstract
Charcot-Marie-Tooth (CMT) disease is a progressive, peripheral neuropathy and the most commonly inherited neurological disorder. Clinical manifestations of CMT mutations are typically limited to peripheral neurons, the longest cells in the body. Currently, mutations in at least 80 different genes are associated with CMT and new mutations are regularly being discovered. A large portion of the proteins mutated in axonal CMT have documented roles in mitochondrial mobility, suggesting that organelle trafficking defects may be a common underlying disease mechanism. This review will focus on the potential role of altered mitochondrial mobility in the pathogenesis of axonal CMT, highlighting the conceptional challenges and potential experimental and therapeutic opportunities presented by this "impaired mobility" model of the disease.
Collapse
Affiliation(s)
- Cara R. Schiavon
- Waitt Advanced Biophotonics Center, Salk Institute for Biological Studies, La Jolla, CA, United States
- Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, United States
| | - Gerald S. Shadel
- Molecular and Cell Biology Laboratory, Salk Institute for Biological Studies, La Jolla, CA, United States
| | - Uri Manor
- Waitt Advanced Biophotonics Center, Salk Institute for Biological Studies, La Jolla, CA, United States
| |
Collapse
|
4
|
Perez-Siles G, Cutrupi A, Ellis M, Screnci R, Mao D, Uesugi M, Yiu EM, Ryan MM, Choi BO, Nicholson G, Kennerson ML. Energy metabolism and mitochondrial defects in X-linked Charcot-Marie-Tooth (CMTX6) iPSC-derived motor neurons with the p.R158H PDK3 mutation. Sci Rep 2020; 10:9262. [PMID: 32504000 PMCID: PMC7275085 DOI: 10.1038/s41598-020-66266-5] [Citation(s) in RCA: 10] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/12/2019] [Accepted: 05/18/2020] [Indexed: 11/09/2022] Open
Abstract
Charcot-Marie-Tooth (CMT) is a group of inherited diseases clinically and genetically heterogenous, characterised by length dependent degeneration of axons of the peripheral nervous system. A missense mutation (p.R158H) in the pyruvate dehydrogenase kinase 3 gene (PDK3) has been identified as the genetic cause for an X-linked form of CMT (CMTX6) in two unrelated families. PDK3 is one of four PDK isoenzymes that regulate the activity of the pyruvate dehydrogenase complex (PDC). The balance between kinases (PDKs) and phosphatases (PDPs) determines the extend of oxidative decarboxylation of pyruvate to generate acetyl CoA, critically linking glycolysis and the energy producing Krebs cycle. We had shown the p.R158H mutation causes hyperactivity of PDK3 and CMTX6 fibroblasts show hyperphosphorylation of PDC, leading to reduced PDC activity and ATP production. In this manuscript we have generated induced pluripotent stem cells (iPSCs) by re-programming CMTX6 fibroblasts (iPSCCMTX6). We also have engineered an isogenic control (iPSCisogenic) and demonstrated that genetic correction of the p.R158H mutation reverses the CMTX6 phenotype. Patient-derived motor neurons (MNCMTX6) show increased phosphorylation of the PDC, energy metabolism defects and mitochondrial abnormalities, including reduced velocity of trafficking mitochondria in the affected axons. Treatment of the MNCMTX6 with a PDK inhibitor reverses PDC hyperphosphorylation and the associated functional deficits founds in the patient motor neurons, demonstrating that the MNCMTX6 and MNisogenic motor neurons provide an excellent neuronal system for compound screening approaches to identify drugs for the treatment of CMTX6.
Collapse
Affiliation(s)
- G Perez-Siles
- Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, Australia. .,Sydney Medical School, University of Sydney, Sydney, Australia.
| | - A Cutrupi
- Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, Australia.,Sydney Medical School, University of Sydney, Sydney, Australia
| | - M Ellis
- Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, Australia
| | - R Screnci
- School of Life Sciences, University of Technology Sydney, Sydney, NSW, Australia
| | - D Mao
- Institute for Integrated Cell-Material Sciences and Institute for Chemical Research, Kyoto University, Kyoto, Japan
| | - M Uesugi
- Institute for Integrated Cell-Material Sciences and Institute for Chemical Research, Kyoto University, Kyoto, Japan
| | - Eppie M Yiu
- Department of Neurology, Royal Children's Hospital, Flemington Road, Parkville, VIC, Australia.,Neuroscience Research, Murdoch Children's Research Institute, Melbourne, VIC, Australia.,Department of Paediatrics, The University of Melbourne, Melbourne, VIC, Australia
| | - Monique M Ryan
- Department of Neurology, Royal Children's Hospital, Flemington Road, Parkville, VIC, Australia.,Neuroscience Research, Murdoch Children's Research Institute, Melbourne, VIC, Australia.,Department of Paediatrics, The University of Melbourne, Melbourne, VIC, Australia
| | - B O Choi
- Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea
| | - G Nicholson
- Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, Australia.,Molecular Medicine Laboratory, Concord Repatriation General Hospital, Sydney, Australia
| | - M L Kennerson
- Northcott Neuroscience Laboratory, ANZAC Research Institute, Sydney, Australia. .,Sydney Medical School, University of Sydney, Sydney, Australia. .,Molecular Medicine Laboratory, Concord Repatriation General Hospital, Sydney, Australia.
| |
Collapse
|